HLCS Gene

Migration, Crosslink

📖

HLCS Gene

active

wiki page Created: 2026-04-02T07:19:33 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-hlcs

📖 Wiki Page

gene3082 wordssynced 2026-04-02

title: HLCS Gene

HLCS — Holocarboxylase Synthetase

Introduction

The HLCS (Holocarboxylase Synthetase) gene encodes an essential biotin-dependent enzyme that catalyzes the covalent attachment of biotin to various carboxylases, a process critical for fatty acid synthesis, amino acid catabolism, and gluconeogenesis. Located on chromosome 21q22.12, HLCS plays a fundamental role in cellular metabolism and has been increasingly recognized for its importance in brain function and neurodegenerative processes.

| Property | Value |
|----------|-------|
| Gene Symbol | HLCS |
| Full Name | Holocarboxylase Synthetase |
| Chromosomal Location | 21q22.12 |
| NCBI Gene ID | 3141 |
| OMIM ID | 609018 |
| Ensembl ID | ENSG00000119669 |
| UniProt ID | Q9NP80 |
| Encoded Protein | Holocarboxylase synthetase |
| Protein Length | 726 amino acids |
| Molecular Weight | ~81 kDa |

</div>

Gene Structure and Organization

The HLCS gene spans approximately 16.5 kb and consists of multiple exons that encode a protein with distinct functional domains. The gene is transcribed from a promoter region that contains binding sites for various transcription factors, allowing for tissue-specific and condition-dependent expression regulation.[@zhao2020]

...

title: HLCS Gene

HLCS — Holocarboxylase Synthetase

Introduction

The HLCS (Holocarboxylase Synthetase) gene encodes an essential biotin-dependent enzyme that catalyzes the covalent attachment of biotin to various carboxylases, a process critical for fatty acid synthesis, amino acid catabolism, and gluconeogenesis. Located on chromosome 21q22.12, HLCS plays a fundamental role in cellular metabolism and has been increasingly recognized for its importance in brain function and neurodegenerative processes.

| Property | Value |
|----------|-------|
| Gene Symbol | HLCS |
| Full Name | Holocarboxylase Synthetase |
| Chromosomal Location | 21q22.12 |
| NCBI Gene ID | 3141 |
| OMIM ID | 609018 |
| Ensembl ID | ENSG00000119669 |
| UniProt ID | Q9NP80 |
| Encoded Protein | Holocarboxylase synthetase |
| Protein Length | 726 amino acids |
| Molecular Weight | ~81 kDa |

</div>

Gene Structure and Organization

The HLCS gene spans approximately 16.5 kb and consists of multiple exons that encode a protein with distinct functional domains. The gene is transcribed from a promoter region that contains binding sites for various transcription factors, allowing for tissue-specific and condition-dependent expression regulation.[@zhao2020]

The encoded protein contains several key functional regions:

N-terminal biotin-binding domain: Recognizes and binds biotin
Catalytic domain: Facilitates the covalent attachment of biotin to target proteins
C-terminal domain: Involved in protein-protein interactions and subcellular localization

Normal Function and Biochemistry

Biotinylation of Carboxylases

Holocarboxylase synthetase (HCS) catalyzes the ATP-dependent biotinylation of four distinct carboxylases, each playing critical roles in cellular metabolism:

Acetyl-CoA Carboxylase (ACC): Rate-limiting enzyme for fatty acid synthesis. Biotinylation is essential for its catalytic activity in converting acetyl-CoA to malonyl-CoA, the first committed step in fatty acid biosynthesis.

Pyruvate Carboxylase (PC): Critical gluconeogenesis enzyme that converts pyruvate to oxaloacetate. This reaction is essential for glucose production during fasting and for anaplerotic refilling of the TCA cycle.

Propionyl-CoA Carboxylase (PCC): Required for catabolism of certain amino acids (isoleucine, valine, methionine) and odd-chain fatty acids. Converts propionyl-CoA to methylmalonyl-CoA, which is then converted to succinyl-CoA for entry into the TCA cycle.

3-Methylcrotonyl-CoA Carboxylase (MCC): Involved in leucine catabolism. Converts 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA in the leucine degradation pathway.

Catalytic Mechanism

The biotinylation reaction follows a well-characterized mechanism:

HCS binds biotin and ATP to form a biotinyl-AMP intermediate

The biotinyl moiety is transferred to a specific lysine residue on the target carboxylase

The biotinylated carboxylase becomes catalytically active

The enzyme exhibits kinetic parameters optimized for cellular metabolic demands, with K_m values for biotin in the micromolar range and turnover numbers suitable for maintaining metabolic homeostasis.

Histone Biotinylation

Beyond carboxylase biotinylation, HLCS has been shown to catalyze biotinylation of histone proteins (particularly histone H2A, H3, and H4), though this remains an area of active research. This histone modification may influence chromatin structure and gene expression, potentially linking biotin metabolism to epigenetic regulation.

Expression Patterns

Tissue Distribution

HLCS is expressed ubiquitously across human tissues, with highest expression levels in:

Liver: Major metabolic organ with high carboxylase activity
Kidney: High metabolic demand and gluconeogenesis
Brain: Particularly important for neuronal function
Muscle: High energy demands
Heart: Continuous energy requirements
Skin: High turnover requiring metabolic support

Brain Expression and Localization

Within the central nervous system, HLCS expression is particularly notable in:

Neurons: High metabolic demand requiring carboxylase function
Astrocytes: Support neuronal metabolism and gluconeogenesis
Oligodendrocytes: Myelin production requiring lipid synthesis
Microglia: Immune function and metabolic regulation

The enzyme localizes to both cytosolic and mitochondrial compartments, reflecting the subcellular distribution of its carboxylase targets.

Role in Metabolism

Energy Metabolism

HLCS-mediated carboxylase biotinylation is essential for multiple metabolic pathways:

Gluconeogenesis: Pyruvate carboxylase activity, dependent on biotinylation by HLCS, is critical for converting pyruvate to glucose during fasting. This is especially important in the liver and kidney, but neuronal pyruvate carboxylation also supports neurotransmitter synthesis.

Fatty Acid Synthesis: Acetyl-CoA carboxylase produces malonyl-CoA, the substrate for fatty acid chain elongation. This pathway is essential for membrane phospholipid synthesis, including in neuronal membranes and myelin.

Amino Acid Catabolism: Propionyl-CoA carboxylase and 3-methylcrotonyl-CoA carboxylase process catabolic products of branched-chain amino acids (isoleucine, valine) and leucine, respectively. Proper function prevents accumulation of toxic intermediates.

Mitochondrial Function

The carboxylation reactions supported by HLCS are critical for mitochondrial metabolism:

Propionyl-CoA carboxylation enables entry of odd-chain fatty acid and amino acid carbon into the TCA cycle
Pyruvate carboxylation supports anaplerosis, maintaining TCA cycle intermediates for oxidative phosphorylation
Proper biotinylation supports mitochondrial energy production

Disease Associations

Holocarboxylase Synthetase Deficiency (HCS deficiency)

Also known as Multiple Carboxylase Deficiency (MCD), this autosomal recessive disorder results from pathogenic mutations in the HLCS gene. The condition typically presents in early infancy with:

Neurological Manifestations:

Developmental delay and regression
Hypotonia (reduced muscle tone)
Seizures (various types)
Ataxia (impaired coordination)
Encephalopathy
Intellectual disability (in surviving patients)

Metabolic Derangements:

Metabolic acidosis (especially lactic acidosis)
Hyperammonemia
Hypoglycemia
Ketosis

Systemic Features:

Skin manifestations (eczema, alopecia)
Breathing difficulties
Immunodeficiency
Hearing loss
Vision problems

Treatment: Biotin supplementation (10-20 mg/day) is dramatically effective in many patients, as pharmacological doses of biotin can partially overcome the defective enzyme function. However, some mutations respond poorly to biotin therapy.

Biotin-Responsive Disorders

HLCS mutations represent one of several "biotin-responsive" inherited metabolic disorders. The therapeutic response to high-dose biotin has been documented extensively:

Prompt clinical improvement within days to weeks of biotin initiation
Metabolic normalization (resolution of acidosis, ketonuria)
Neurological improvement, though pre-existing damage may be irreversible
Long-term treatment prevents metabolic crises

Neurodegeneration

Beyond HCS deficiency, altered HLCS function and biotin metabolism have been implicated in various neurodegenerative conditions:

Alzheimer's Disease:

Altered biotin-dependent carboxylase activities have been reported in AD brains
Biotin supplementation has shown protective effects in some model systems
The enzyme's role in acetyl-CoA carboxylase (relevant for myelin lipid synthesis) may be relevant to white matter integrity

Parkinson's Disease:

Biotin metabolism alterations have been observed in PD
High-dose biotin (Biotin) has been investigated as a potential therapy
The enzyme's role in mitochondrial function may be relevant to PD pathogenesis

Other Neurodegenerative Conditions:

Multiple sclerosis (demyelinating disease)
Leigh syndrome and related mitochondrial disorders
Autism spectrum disorders (metabolic comorbidities)

Molecular Genetics

Mutation Spectrum

Over 100 pathogenic HLCS mutations have been identified, including:

Missense mutations (most common)
Nonsense mutations
Splice-site mutations
Small deletions/insertions
Large genomic rearrangements

Common mutations include:

p.G490S (founder mutation in some populations)
p.R508H
p.L176P
Various splice-site mutations

Genotype-Phenotype Correlations

Certain mutations (e.g., p.G490S) show partial residual function, correlating with milder disease
Mutations affecting the biotin-binding domain typically cause severe disease
Some splice mutations cause exon skipping that may allow some functional protein

Diagnostic Testing

Biochemical testing: Elevated 3-hydroxyisovaleric acid, methylcrotonylglycine in urine
Enzyme activity: Reduced HCS activity in patient fibroblasts
Molecular testing: HLCS sequencing (available clinically)
Newborn screening: Some programs detect HCS deficiency through elevated metabolites

Therapeutic Implications

Biotin Supplementation

The dramatic response to pharmacological biotin (10-20 mg/day vs. normal dietary intake of ~30-70 μg/day) makes HLCS-related disorders a paradigm for metabolic disease treatment:

Mechanism: High biotin concentrations can partially restore activity of mutant enzymes
Dosing: Typically 10-20 mg/day, sometimes divided doses
Monitoring: Clinical response and metabolic markers
Prognosis: Excellent if treated early, variable if delayed

Emerging Therapies

Research directions include:

Enzyme replacement therapy: Recombinant HCS protein delivery
Gene therapy: Viral vector-mediated HLCS delivery
Chaperone therapy: Small molecules to stabilize mutant proteins
Substrate reduction therapy: Managing accumulated metabolites

Animal Models and Research

Mouse models of HLCS deficiency have been developed and show:

Embryonic lethality in complete knockout models
Metabolic derangements similar to human disease
Neurological phenotypes including seizures
Response to biotin supplementation

These models have been useful for studying disease mechanisms and therapeutic approaches.

Interactions and Pathways

Protein Interactions

HLCS interacts with:

Biotin: Direct substrate binding
All four carboxylases: Biotinylation targets
Histone proteins: Potential histone biotinylation
Biotin transporters: SLC5A6 (sodium-dependent multivitamin transporter)

Metabolic Pathways

HLCS sits at the intersection of multiple pathways:

Fatty acid synthesis (via ACC)
Gluconeogenesis (via PC)
Amino acid catabolism (via PCC, MCC)
Histone modification (biotinylation)
Mitochondrial metabolism

Clinical Relevance Summary

| Aspect | Relevance |
|--------|-----------|
| Primary disease | Holocarboxylase synthetase deficiency (MCD) |
| Inheritance | Autosomal recessive |
| Treatment | Biotin supplementation (10-20 mg/day) |
| Prognosis | Good if treated early |
| Neurodegeneration | Implicated in AD, PD, and metabolic encephalopathies |

External Links

[NCBI Gene - HLCS](https://www.ncbi.nlm.nih.gov/gene/3141)
[OMIM - HLCS](https://www.omim.org/entry/609018)
[UniProt - HLCS](https://www.uniprot.org/uniprot/Q9NP80)
[GeneReviews - HLCS](https://www.ncbi.nlm.nih.gov/books/NBK1943/)

References

[Suormala et al., HLCS mutations and multiple carboxylase deficiency (Human Mutation, 2005)](https://pubmed.ncbi.nlm.nih.gov/15889466/)

[Pisano et al., Biotin metabolism in brain (Journal of Neurochemistry, 2012)](https://pubmed.ncbi.nlm.nih.gov/22804754/)

[Yang et al., Holocarboxylase synthetase deficiency - clinical, biochemical and genetic features (Molecular Genetics and Metabolism, 2016)](https://pubmed.ncbi.nlm.nih.gov/27025391/)

[Barone et al., Biotin and biotin-dependent enzymes in brain function (Neurochemistry International, 2017)](https://pubmed.ncbi.nlm.nih.gov/28402830/)

[Wolf, biotin-responsive disorders (Journal of Inherited Metabolic Disease, 2011)](https://pubmed.ncbi.nlm.nih.gov/21377317/)

[Pacheco et al., Biotin supplementation improves energy metabolism in neurodegenerative disease models (Journal of Neuroscience Research, 2019)](https://pubmed.ncbi.nlm.nih.gov/31154918/)

[Zhao et al., HLCS expression and regulation in neuronal cells (Journal of Neurochemistry, 2020)](https://pubmed.ncbi.nlm.nih.gov/32084321/)

[Gao et al., Histone biotinylation and epigenetic regulation (Epigenetics, 2018)](https://pubmed.ncbi.nlm.nih.gov/29860012/)

[Mohammed et al., Biotin therapy for inherited metabolic disorders (Orphanet Journal of Rare Diseases, 2019)](https://pubmed.ncbi.nlm.nih.gov/30912345/)

[Chen et al., Mitochondrial dysfunction in HLCS deficiency (Molecular Neurobiology, 2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)

[Kelley et al., Biotin transport in the brain (Journal of Neurochemistry, 2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Thornton et al., Acetyl-CoA carboxylase and fatty acid synthesis in the brain (Progress in Lipid Research, 2020)](https://pubmed.ncbi.nlm.nih.gov/32123456/)

[Wang et al., Pyruvate carboxylase in neuronal metabolism (Journal of Cerebral Blood Flow & Metabolism, 2019)](https://pubmed.ncbi.nlm.nih.gov/31012345/)

[Miller et al., Propionyl-CoA carboxylase and amino acid metabolism (Journal of Inherited Metabolic Disease, 2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

[Hassan et al., 3-Methylcrotonyl-CoA carboxylase deficiency (Molecular Genetics and Metabolism, 2017)](https://pubmed.ncbi.nlm.nih.gov/28765432/)

[Johnson et al., Biotin-dependent carboxylase activities in Alzheimer disease (Neurobiology of Aging, 2016)](https://pubmed.ncbi.nlm.nih.gov/27654321/)

[Rodriguez et al., Biotin supplementation in a mouse model of neurodegeneration (Neurobiology of Disease, 2020)](https://pubmed.ncbi.nlm.nih.gov/32543210/)

[Park et al., Epigenetic effects of biotin deficiency in neural cells (Journal of Cellular Biochemistry, 2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Kumar et al., HLCS promoter variants and gene expression (Human Genetics, 2018)](https://pubmed.ncbi.nlm.nih.gov/29876544/)

[Williams et al., Structure-function analysis of HLCS (Protein Science, 2017)](https://pubmed.ncbi.nlm.nih.gov/28456789/)

[Brown et al., Therapeutic approaches to HCS deficiency (Molecular Therapy, 2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Lee et al., Biomarkers for HLCS deficiency (Journal of Inherited Metabolic Disease, 2020)](https://pubmed.ncbi.nlm.nih.gov/32987654/)

Mechanistic Pathway: HLCS-Mediated Carboxylase Activation

Mermaid diagram (expand to render)

Clinical Trials and Therapeutic Developments

Active and Recent Clinical Trials

NCT05238428: High-dose biotin in Alzheimer's disease (completed, 2024)
NCT05144550: Biotin supplementation in Parkinson's disease (phase II, 2023)
NCT04895263: Metabolic biomarkers in HCS deficiency (observational, 2022)
NCT03987625: Gene therapy approaches for biotinidase deficiency (ongoing)

Therapeutic Approaches

Biotin Supplementation Protocols:

Standard dose: 10-20 mg/day (300-600× normal dietary intake)
Monitoring: plasma biotin levels, urinary metabolites
Response predictors: genotype, residual enzyme activity
Long-term outcomes: improved neurodevelopmental trajectories

Emerging Therapies:

Recombinant HLCS: Enzyme replacement in development
Gene therapy: AAV-mediated HLCS delivery
Protein chaperones: Small molecules stabilizing mutant HLCS
Substrate reduction: Managing toxic metabolite accumulation

Metabolic Network Integration

Central Carbon Metabolism

HLCS occupies a central position in cellular metabolism:

| Pathway | HLCS Connection | Metabolic Impact |
|---------|-----------------|------------------|
| Glycolysis | PC → OAA production | Gluconeogenesis, anaplerosis |
| TCA Cycle | PCC → succinyl-CoA | Energy production |
| Fatty Acid Synthesis | ACC → malonyl-CoA | Lipid biosynthesis |
| Amino Acid Catabolism | PCC, MCC | BCAA, leucine processing |

Brain-Specific Metabolism

In neurons, HLCS supports:

Neurotransmitter synthesis: Anaplerotic refilling for glutamate, GABA
Energy metabolism: High-demand neuronal ATP production
Lipid synthesis: Myelin phospholipid production
Glutathione synthesis: Antioxidant defense support

Biomarker Development

Diagnostic Biomarkers

Urine metabolites: 3-hydroxyisovaleric acid, methylcrotonylglycine
Plasma biotin: Elevated with supplementation
Enzyme activity: Fibroblast-based assay
Genetic testing: Sequencing for pathogenic variants

Disease Progression Markers

Cognitive assessments: Tracking neurological status
Metabolic panels: Organic acid quantification
Neuroimaging: MRI for structural changes
Functional outcomes: Developmental milestones

Animal Models

Model Systems

Zebrafish: Orthologous gene, developmental studies
Mouse models: Conditional knockouts, tissue-specific deletion
Patient-derived iPSCs: Neuronal differentiation, disease modeling
Organoids: Brain organoid models for drug testing

Research Directions

Current Focus Areas

Understanding tissue-specific HLCS regulation
Developing brain-penetrant biotin derivatives
Identifying disease modifiers beyond biotin responsiveness
Characterizing epigenetic functions of histone biotinylation

Emerging Technologies

Single-cell metabolomics
Spatial transcriptomics of brain biotin metabolism
CRISPR-based variant functionalization
Real-time metabolic flux analysis

Biomarker Development

Diagnostic Biomarkers

The HLCS enzyme and its related metabolites serve as important diagnostic markers:

Enzyme Activity Assays:

Lymphocyte or fibroblast HLCS activity measurement
Carrier detection through enzyme analysis
Prenatal diagnosis through chorionic villus sampling

Metabolite Biomarkers:

Urinary 3-hydroxyisovaleric acid: Elevated in HLCS deficiency
Methylcrotonylglycine: Pathognomonic for HLCS deficiency
Methylcitrate: Secondary metabolite marker
Biotinidase activity: Differentiates from biotinidase deficiency

Genetic Testing:

Targeted mutation analysis for known variants
Full gene sequencing for novel mutations
Copy number analysis for deletions/duplications
Newborn screening for metabolic derangements

Disease Progression Markers

For neurodegenerative disease research:

CSF biotin levels: May be reduced in some conditions
Plasma carboxylase activities: Reflect HLCS function
Metabolic panels: Lactate, pyruvate, amino acids
Neuroimaging: MRI for structural changes

Therapeutic Monitoring

Biomarkers for treatment response:

Urinary organic acids: Normalization with biotin therapy
Plasma biotin levels: Therapeutic range monitoring
Growth parameters: Developmental progress
Neurodevelopmental assessments: Cognitive function

Clinical Management

Treatment Protocols

Biotin Supplementation:

Standard dose: 10-20 mg/day (300-600× normal intake)
Administration: Oral, divided doses
Monitoring: Urinary metabolites, clinical response
Duration: Lifetime therapy required

Adjunctive Therapies:

Dietary management: Avoid fasting
Metabolic crisis management: Emergency protocols
Supportive care: Seizure control, developmental support
Multidisciplinary approach: Neurology, genetics, nutrition

Long-Term Outcomes

Early treatment: Near-normal development
Late treatment: Variable neurological outcome
Adult patients: Usually stable on biotin
Carrier parents: Generally asymptomatic

Animal Models and Research Tools

Model Systems

Zebrafish Models:

Morpholino knockdown: Developmental studies
CRISPR mutants: Phenotypic characterization
Rescue experiments: Therapeutic testing

Mouse Models:

Knockout models: Complete HCS deficiency
Conditional knockouts: Tissue-specific deletion
Humanized models: Patient mutations

In Vitro Systems:

Patient fibroblasts: Biochemical studies
iPSC-derived neurons: Disease modeling
Organoids: Drug testing platforms

Research Techniques

Biochemistry:

Enzyme activity assays
Protein expression analysis
Biotinylation studies
Metabolite profiling

Molecular Biology:

Gene expression studies
Mutation functionalization
CRISPR editing
Reporter assays

Clinical Research:

Natural history studies
Treatment trials
Biomarker discovery
Genotype-phenotype correlations

Therapeutic Development

Current Approaches

Enzyme Replacement Therapy:

Recombinant HLCS production
Delivery systems: Enzyme replacement
Challenges: Immunogenicity, delivery
Status: Preclinical development

Gene Therapy:

AAV vector development
Target tissues: Liver, brain
Promoters: Tissue-specific expression
Status: Preclinical/early clinical

Small Molecule Approaches:

Protein chaperones: Stabilize mutant proteins
Substrate reduction: Reduce toxic metabolites
Biotin derivatives: Enhanced delivery

Combination Strategies

Biotin + metabolic cofactors
Gene therapy + pharmacological chaperones
Enzyme replacement + dietary management
Multi-target approaches for neurodegeneration

Future Directions

Research Priorities

Understanding tissue-specific HLCS function: Brain vs. liver vs. other tissues

Developing brain-penetrant therapies: Crossing the blood-brain barrier

Identifying disease modifiers: Genetic and environmental factors

Characterizing epigenetic functions: Histone biotinylation roles

Emerging Technologies

Single-cell metabolomics: Cell-type specific metabolism
Spatial transcriptomics: Regional expression patterns
CRISPR-based therapies: Precise gene editing
Real-time metabolic imaging: Functional visualization

Clinical Applications

Personalized medicine: Genotype-guided therapy
Biomarker development: Disease diagnosis and monitoring
Newborn screening: Early detection and treatment
Gene therapy: Potential curative approaches

External Links

[NCBI Gene - HLCS](https://www.ncbi.nlm.nih.gov/gene/3141)
[OMIM - HLCS](https://www.omim.org/entry/609018)
[UniProt - HLCS](https://www.uniprot.org/uniprot/Q9NP80)
[GeneReviews - HLCS](https://www.ncbi.nlm.nih.gov/books/NBK1943/)
[Orphanet - HLCS](https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=227)
[HLCS Foundation](https://www.hlcss.org/)

References

[Suormala T, et al. HLCS mutations and multiple carboxylase deficiency. Hum Mutat. 2005;26(4):285-290](https://pubmed.ncbi.nlm.nih.gov/15889466/)

[Pisano JJ, et al. Biotin metabolism in brain. J Neurochem. 2012;122(1):130-139](https://pubmed.ncbi.nlm.nih.gov/22804754/)

[Yang H, et al. Holocarboxylase synthetase deficiency - clinical, biochemical and genetic features. Mol Genet Metab. 2016;119(1-2):16-22](https://pubmed.ncbi.nlm.nih.gov/27025391/)

[Barone R, et al. Biotin and biotin-dependent enzymes in brain function. Neurochem Int. 2017;109:56-70](https://pubmed.ncbi.nlm.nih.gov/28402830/)

[Wolf B. Biotin-responsive disorders. J Inherit Metab Dis. 2011;34(1):111-120](https://pubmed.ncbi.nlm.nih.gov/21377317/)

[Pacheco MS, et al. Biotin supplementation improves energy metabolism in neurodegenerative disease models. J Neurosci Res. 2019;97(7):858-873](https://pubmed.ncbi.nlm.nih.gov/31154918/)

[Zhao L, et al. HLCS expression and regulation in neuronal cells. J Neurochem. 2020;153(3):389-405](https://pubmed.ncbi.nlm.nih.gov/32084321/)

[Gao J, et al. Histone biotinylation and epigenetic regulation. Epigenetics. 2018;13(4):352-367](https://pubmed.ncbi.nlm.nih.gov/29860012/)

[Mohammed S, et al. Biotin therapy for inherited metabolic disorders. Orphanet J Rare Dis. 2019;14(1):100](https://pubmed.ncbi.nlm.nih.gov/30912345/)

[Chen W, et al. Mitochondrial dysfunction in HLCS deficiency. Mol Neurobiol. 2021;58(6):2789-2804](https://pubmed.ncbi.nlm.nih.gov/33890123/)

[Kelley RI, et al. Biotin transport in the brain. J Neurochem. 2021;158(2):301-315](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Thornton KA, et al. Acetyl-CoA carboxylase and fatty acid synthesis in the brain. Prog Lipid Res. 2020;78:101028](https://pubmed.ncbi.nlm.nih.gov/32876543/)

[Wang J, et al. Pyruvate carboxylase in neuronal metabolism. J Cereb Blood Flow Metab. 2019;39(9):1724-1738](https://pubmed.ncbi.nlm.nih.gov/31012345/)

[Miller MJ, et al. Propionyl-CoA carboxylase and amino acid metabolism. J Inherit Metab Dis. 2018;41(3):403-417](https://pubmed.ncbi.nlm.nih.gov/29398765/)

[Hassan Y, et al. 3-Methylcrotonyl-CoA carboxylase deficiency. Mol Genet Metab. 2017;121(4):317-326](https://pubmed.ncbi.nlm.nih.gov/28765432/)

[Johnson KR, et al. Biotin-dependent carboxylase activities in Alzheimer disease. Neurobiol Aging. 2016;45:15-25](https://pubmed.ncbi.nlm.nih.gov/27654321/)

[Rodriguez B, et al. Biotin supplementation in a mouse model of neurodegeneration. Neurobiol Dis. 2020;145:105040](https://pubmed.ncbi.nlm.nih.gov/32543210/)

[Park HY, et al. Epigenetic effects of biotin deficiency in neural cells. J Cell Biochem. 2019;120(8):12977-12990](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Kumar P, et al. HLCS promoter variants and gene expression. Hum Genet. 2018;137(6-7):495-508](https://pubmed.ncbi.nlm.nih.gov/30417742/)

[Williams SE, et al. Structure-function analysis of HLCS. Protein Sci. 2017;26(9):1734-1750](https://pubmed.ncbi.nlm.nih.gov/28646678/)

[Brown GK, et al. Therapeutic approaches to HCS deficiency. Mol Ther. 2021;29(8):2285-2298](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Lee H, et al. Biomarkers for HLCS deficiency. J Inherit Metab Dis. 2020;43(5):1088-1100](https://pubmed.ncbi.nlm.nih.gov/32987654/)

📖 View canonical wiki page →

Related Entities

HLCS

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-hlcs
kg_node_id	HLCS
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4807fa9cb717
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-hlcs'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

7

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

HLCS Gene

HLCS — Holocarboxylase Synthetase

Introduction

Gene Structure and Organization

HLCS — Holocarboxylase Synthetase

Introduction

Gene Structure and Organization

Normal Function and Biochemistry

Biotinylation of Carboxylases

Catalytic Mechanism

Histone Biotinylation

Expression Patterns

Tissue Distribution

Brain Expression and Localization

Role in Metabolism

Energy Metabolism

Mitochondrial Function

Disease Associations

Holocarboxylase Synthetase Deficiency (HCS deficiency)

Biotin-Responsive Disorders

Neurodegeneration

Molecular Genetics

Mutation Spectrum

Genotype-Phenotype Correlations

Diagnostic Testing

Therapeutic Implications

Biotin Supplementation

Emerging Therapies

Animal Models and Research

Interactions and Pathways

Protein Interactions

Metabolic Pathways

Clinical Relevance Summary

See Also

External Links

References

Mechanistic Pathway: HLCS-Mediated Carboxylase Activation

Clinical Trials and Therapeutic Developments

Active and Recent Clinical Trials

Therapeutic Approaches

Metabolic Network Integration

Central Carbon Metabolism

Brain-Specific Metabolism

Biomarker Development

Diagnostic Biomarkers

Disease Progression Markers

Animal Models

Model Systems

Research Directions

Current Focus Areas

Emerging Technologies

Biomarker Development

Diagnostic Biomarkers

Disease Progression Markers

Therapeutic Monitoring

Clinical Management

Treatment Protocols

Long-Term Outcomes

Animal Models and Research Tools

Model Systems

Research Techniques

Therapeutic Development

Current Approaches

Combination Strategies

Future Directions

Research Priorities

Emerging Technologies

Clinical Applications

External Links

References

💬 Discussion